Answers are grounded in this paper and cite their sources.
Highlights the debate surrounding ACE inhibitors and angiotensin-II receptor blockers in COVID-19 patients with hypertension, suggesting targeted evaluation of disease trajectory.
Cardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.
No takes yet. Share an insight, caveat, or question.
Murthy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: